Greer Murphy M.D., Ph.D.

Publication Details

  • The apolipoprotein E epsilon 4 allele and antidepressant efficacy in cognitively intact elderly depressed patients BIOLOGICAL PSYCHIATRY Murphy, G. M., Kremer, C., Rodrigues, H., Schatzberg, A. F. 2003; 54 (7): 665-673

    Abstract:

    Patients vary in response to antidepressant medications. Apolipoprotein E (APOE) genotype affects vulnerability to stress and risk for cognitive impairment. We sought to determine if the APOE epsilon4 allele influences response in geriatric depression to mirtazapine and paroxetine, two frequently prescribed antidepressants. We hypothesized that epsilon4 carriers would show impaired antidepressant response.The study was a double-blind, randomized, 8-week trial with a 16-week extension phase involving 246 cognitively intact patients aged 65 years or older with major depression. Patients were treated with mirtazapine 15-45 mg (n = 124) or paroxetine 20-40 mg (n = 122). The outcome measures were the Hamilton Depression Rating Scale, the Geriatric Depression Scale, and the Clinical Global Impression Scale. APOE genotype was determined by restriction isotyping.Patients carrying the epsilon4 allele showed a rapid onset of mirtazapine action, whereas paroxetine-treated patients with the epsilon4 allele were slow to respond. This difference could not be attributed to dosage, compliance, severity of adverse events, ethnicity, baseline depression or cognition, gender, or age.The APOE epsilon4 allele may affect antidepressant treatment outcome, but the effect depends on the medication. Further studies should determine if this result applies to other samples and medications.

    View details for DOI 10.1016/S0006-3223(03)00174-4

    View details for Web of Science ID 000185500500001

    View details for PubMedID 14512205

Stanford Medicine Resources:

Footer Links: